CAPADENOSON (C005B-310000)

Catalog No.: C005B-310000
Mfr. No.: SML2852-5MG
Mfr. Name: Sigma-Aldrich
Qty/UOM: 5
UOM: MG

Price: $206.99

List Price: $229.99

Biochem/physiol Actions Capadenoson (BAY 68-4986) is an adenosine receptor A1 (A1AR) partial agonist (GTPγ:S binding EC 50 /E max = 0.1 nM/74% vs.

Enjoy exclusive benefits including discounted pricing on orders by contacting our Sales Executives to open an account. Contact Us

Current Stock:

Quantity:

Shipping Lead-Time: 3-5 Days

Adding to cart… The item has been added

Description
Specifications

Biochem/physiol Actions

Capadenoson (BAY 68-4986) is an adenosine receptor A1 (A1AR) partial agonist (GTPγS binding EC₅₀/E_max = 0.1 nM/74% vs. 0.3 nM/100% with CCPA; human cortex membranes) that exerts additional biased A2BAR agonism toward cAMP signal transduction (pEC₅₀ = 8.94/cAMP, 6.20/Ca+2, 6.12/pERK, 5.03/IP1), while exhibiting weak A2A & A3 potency. Capadenoson offers cardioprotection efficacy in an ischemia-reperfusion injury rat model in vivo (25/28% infarct size reduction with 0.1/0.3 mg/kg iv.) without the risk of a full atrioventricular (AV) block (isolated perfused rat heart rate = 100% up to 10 nM, 90% at ≥10 μM) seen with the full A1 agonist CCPA.

UPC:: 51182215
Condition:: New
Weight:: 1.00 Ounces
HazmatClass:: No
MPN:: SML2852-5MG
CAS:: 544417-40-5

Cenmed Satisfaction Guarantee

At Cenmed, your confidence and satisfaction are paramount. We guarantee the quality and reliability of our extensive range of clinical and laboratory supplies. If you're not completely satisfied with your purchase, we offer a straightforward return process and dedicated support to resolve your concerns promptly. Our commitment ensures that you can order with confidence, knowing that Cenmed is dedicated to superior service and customer satisfaction. Trust us to meet your needs with every order, backed by our promise of excellence. Learn more in Help & FAQs.

"Cenmed provides me access to the same products/services normally reserved for much larger labs than mine. I was presently surprised by their product offering."